NCT05353439
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 139 versions: 3 with changes below, 47 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Withdrawal of tazemetostat supply led to early study closure. Show 5 more changesShow less
- Primary endpoint(s) modified
- Results posted: Nov 10, 2026
- Enrollment increased: 18 → 22 participants
- Study completion date changed from estimate of Mar 13, 2027 to Apr 21, 2026
- Site details revised at 5 of 15 sites
- Minor Enrollment target: estimated 60 to confirmed 18
- Primary completion date changed from estimate of Apr 1, 2027 to Feb 11, 2026
- Study completion date: Apr 1, 2027 to Mar 13, 2027
- Minor Trial status: Recruiting to Active, Not Recruitingv117
- Stopped: terminated, suspended or withdrawn
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients receive tazemetostat PO BID for 7 days prior to cycle 1 and then on days 1-21 of each cycle, pembrolizumab IV over 30 minutes on day 1 of each cycle, and topotecan IV over 30 minutes on days 1-3 or days 1-5 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and undergo biopsy and collection of blood on study.
Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography
Biologicals: Pembrolizumab
Drugs: Tazemetostat Hydrobromide, Topotecan Hydrochloride
Sites
15 sites in 1 country